Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James R Shoblock

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
The Journal of Pharmacology and Experimental Therapeutics|October 2, 2014
Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432Brian Lord, Leah Aluisio, James R Shoblock, et al.
British Journal of Pharmacology|July 30, 2013
Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567Anindya Bhattacharya, Qi Wang, Hong Ao, et al.
Psychopharmacology|November 19, 2010
JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in ratsRuggero Galici, Amir H Rezvani, Leah Aluisio, et al.
Psychopharmacology|December 3, 2009
In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y(2) receptorJames R Shoblock, Natalie Welty, Diane Nepomuceno, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
The Journal of Pharmacology and Experimental Therapeutics|October 2, 2014
Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432Brian Lord, Leah Aluisio, James R Shoblock, et al.
British Journal of Pharmacology|July 30, 2013
Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567Anindya Bhattacharya, Qi Wang, Hong Ao, et al.
Psychopharmacology|November 19, 2010
JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in ratsRuggero Galici, Amir H Rezvani, Leah Aluisio, et al.
Psychopharmacology|December 3, 2009
In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y(2) receptorJames R Shoblock, Natalie Welty, Diane Nepomuceno, et al.
Pageof 2